Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $156.50

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have received an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $156.50.

Several equities research analysts have commented on ABVX shares. Wolfe Research set a $136.00 price target on Abivax in a research note on Wednesday, June 3rd. Guggenheim reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Leerink Partners boosted their target price on Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $187.00 target price on shares of Abivax in a research report on Wednesday, July 1st.

Institutional Investors Weigh In On Abivax

Several institutional investors have recently bought and sold shares of ABVX. Readystate Asset Management LP increased its position in shares of Abivax by 19.6% in the second quarter. Readystate Asset Management LP now owns 241,530 shares of the company’s stock worth $32,186,000 after acquiring an additional 39,508 shares in the last quarter. Troluce Capital Advisors LLC acquired a new position in shares of Abivax during the 2nd quarter valued at $133,000. Seven Fleet Capital Management LP lifted its holdings in shares of Abivax by 158.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 111,334 shares of the company’s stock valued at $14,836,000 after acquiring an additional 68,282 shares in the last quarter. FNY Investment Advisers LLC lifted its holdings in shares of Abivax by 7.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 7,605 shares of the company’s stock valued at $1,013,000 after acquiring an additional 519 shares in the last quarter. Finally, Versant Capital Management Inc purchased a new stake in Abivax during the 2nd quarter worth $30,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Trading Down 0.8%

Shares of ABVX opened at $113.35 on Thursday. Abivax has a twelve month low of $69.81 and a twelve month high of $148.83. The firm has a market capitalization of $9.89 billion, a P/E ratio of -21.76 and a beta of 1.03. The stock’s fifty day simple moving average is $124.44 and its 200 day simple moving average is $119.00.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.